| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10916063 | Nuclear Medicine and Biology | 2013 | 7 Pages |
Abstract
89Zr-DFO-panitumumab can prepared with high radiochemical purity and specific activity. 89Zr-DFO-panitumumab microPET/CT showed uptake corresponding to HER-1 expression. Due to poor clearance, initial dosimetry estimates suggest that only a low dose 89Zr-DFO-panitumumab shows favorable human dosimetry; however due to high tumor uptake, the use of 89Zr-DFO-panitumumab is expected to be clinically feasible.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Sibaprasad Bhattacharyya, Karen Kurdziel, Ling Wei, Lisa Riffle, Gurmeet Kaur, G. Craig Hill, Paula M. Jacobs, James L. Tatum, James H. Doroshow, Joseph D. Kalen,